GlassScriptPhysician profile
Alexander Deak
NPI 1386057651
$8,517.85
in general payments reported to CMS, 2019-2025
58 companies · $3,092 in 2025
The $3,092 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $175 · 2022: $957 · 2023: $1,823 · 2024: $2,471 · 2025: $3,092.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,286 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,286.40 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $1,172.17 | 2024-2025 | |
| Pfizer INC. | $700.67 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $651.71 | 2022-2025 | Imfinzi, Calquence, Enhertu |
| Novartis Pharmaceuticals Corporation | $651.47 | 2021-2025 | |
| Abbvie INC. | $424.18 | 2022-2025 | Venclexta |
| E.R. Squibb & Sons, L.L.C. | $409.81 | 2022-2025 | Opdivo, Opdualag, Camzyos |
| Astellas Pharma US INC | $348.01 | 2021-2025 | Vyloy, Padcev, Xtandi |
| Takeda Pharmaceuticals U.S.A., INC. | $294.95 | 2022-2025 | Ninlaro, Fruzaqla, Iclusig |
| Janssen Biotech, INC. | $241.99 | 2022-2025 | Rybrevant, Carvykti, Erleada |
| Daiichi Sankyo INC. | $223.35 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Glaxosmithkline, LLC. | $206.25 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Bayer Healthcare Pharmaceuticals INC. | $194.06 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $193.76 | 2023-2024 | Libtayo |
| Genzyme Corporation | $179.25 | 2021-2025 | |
| Celgene Corporation | $150.95 | 2023-2025 | Reblozyl, Pomalyst, Opdualag |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $146.97 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Array Biopharma INC | $138.30 | 2022-2025 | Braftovi, Lorbrena, Mektovi |
| Incyte Corporation | $125.91 | 2023-2025 | Monjuvi, Pemazyre, Zynyz |
| Beone Medicines USA, INC. | $102.81 | 2025 | Brukinsa, Tevimbra |
| Genentech USA, INC. | $100.74 | 2023-2025 | Polivy, Itovebi, Venclexta |
| Pharmacyclics LLC, An Abbvie Company | $99.44 | 2022-2023 | Imbruvica, Epkinly |
| Seagen INC. | $90.97 | 2022-2023 | Padcev |
| Mirati Therapeutics, INC. | $87.00 | 2023-2024 | Krazati |
| Exelixis INC. | $86.24 | 2022-2025 | Cabometyx |
| Eisai INC. | $86.03 | 2022-2024 | |
| Adc Therapeutics America, INC. | $81.88 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $80.92 | 2022-2025 | Onivyde |
| Sobi, INC | $79.87 | 2022-2024 | |
| Tersera Therapeutics LLC | $79.50 | 2022-2025 | Zoladex |
| Kite Pharma, INC. | $74.85 | 2023-2025 | Yescarta |
| Amgen INC. | $63.43 | 2022-2023 | Nplate, Vectibix, Xgeva |
| Stemline Therapeutics INC. | $59.91 | 2023-2025 | Orserdu |
| Genmab U.S., INC. | $58.10 | 2022-2024 | Tivdak |
| Rigel Pharmaceuticals, INC. | $57.46 | 2024 | Tavalisse, Rezlidhia |
| Blueprint Medicines Corporation | $55.10 | 2022-2023 | Ayvakit |
| Servier Pharmaceuticals LLC | $49.38 | 2024 | |
| Puma Biotechnology, INC. | $45.82 | 2023-2025 | |
| Beigene USA, INC. | $45.57 | 2024-2025 | Brukinsa, Tevimbra |
| Morphosys, US INC. | $44.70 | 2022-2023 | Monjuvi |
| Janssen Pharmaceuticals, INC | $43.72 | 2024 | Xarelto |
| G1 Therapeutics, INC. | $42.03 | 2022 | |
| Myriad Genetic Laboratories, INC. | $39.62 | 2024 | Myrisk |
| Sanofi US Services INC. | $37.92 | 2024 | |
| Tempus Ai, INC | $32.61 | 2025 | Xt Cdx |
| Caris Mpi, INC. | $32.41 | 2025 | Mi Cancer Seek |
| Pharmacosmos Therapeutics INC. | $31.50 | 2025 | Monoferric |
| Gilead Sciences, INC. | $27.37 | 2023-2024 | Trodelvy |
| Aveo Pharmaceuticals, INC. | $27.21 | 2023 | Fotivda |
| Pharmaand Gmbh | $25.84 | 2025 | Rubraca |
| Tolmar, INC. | $25.84 | 2025 | Eligard, Rubraca |
| Amneal Pharmaceuticals LLC | $25.61 | 2024 | Avastin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.20 | 2025 | |
| Pharmaessentia USA Corporation | $24.98 | 2023 | Besremi |
| Adaptive Biotechnologies Corporation | $21.93 | 2024 | Clonoseq |
| Lilly USA, LLC | $20.29 | 2023 | Retevmo, Jaypirca |
| Emd Serono, INC. | $18.82 | 2023 | Bavencio |
| Azurity Pharmaceuticals, INC. | $17.59 | 2025 | Danziten |
| Spectrum Pharmaceuticals INC. | $13.88 | 2023 | Rolvedon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Deak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.